(NASDAQ: AUTL) Autolus Therapeutics's forecast annual revenue growth rate of 215.23% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.37%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.57%.
Autolus Therapeutics's revenue in 2025 is $9,011,000.On average, 4 Wall Street analysts forecast AUTL's revenue for 2025 to be $17,068,447,112, with the lowest AUTL revenue forecast at $12,488,153,428, and the highest AUTL revenue forecast at $20,748,384,402. On average, 4 Wall Street analysts forecast AUTL's revenue for 2026 to be $44,112,140,449, with the lowest AUTL revenue forecast at $31,745,347,504, and the highest AUTL revenue forecast at $70,697,804,418.
In 2027, AUTL is forecast to generate $75,914,708,356 in revenue, with the lowest revenue forecast at $48,301,472,400 and the highest revenue forecast at $120,037,760,603.